Skip to main content

Table 2 Results of logistic regression analysis to determine variables associated with SGLT2i initiation according to baseline characteristics of study participants in the high-risk CKD group eligible for SGLT2i

From: Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study

  

CRUDE

  

ADJUST

 

Variable

OR

95 % CI

p-value

OR

95 % CI

p-value

Age

 17–44(reference)

  45–64

1.2027

0.95–1.52

0.1260

1.3581

1.02–1.81

0.0384

  >=65

0.3282

0.25–0.43

< 0.0001

0.4068

0.28–0.60

< 0.0001

Female sex

0.9229

0.79–1.08

0.3190

1.0209

0.83–1.26

0.8491

BMI, kg/m2

1.2654

1.21–1.33

< 0.0001

1.2723

1.20–1.35

< 0.0001

DM duration (per year)

0.9564

0.94–0.98

< 0.0001

0.9806

0.92–1.04

0.5203

DM duration, yr

 < 5 (reference)

  5 ~ 9

1.3008

0.99–1.71

0.0601

1.1535

0.78–1.71

0.4759

  10 ~ 14

0.8289

0.64–1.08

0.1637

0.9427

0.67–1.33

0.7388

  > 15

0.6581

0.51–0.84

0.0009

0.9195

0.47–1.82

0.8090

HbA1c

1.5200

1.34–1.72

< 0.0001

1.4504

1.24–1.70

< 0.0001

Albuminuria categories

 A2(reference)

  A3

0.9796

0.84–1.15

0.8000

0.9213

0.75–1.14

0.4460

  Diabetic retinopathy

1.2183

1.04–1.42

0.0122

1.4757

1.18–1.84

0.0005

  Cancer

0.5636

0.38–0.83

0.0033

0.6862

0.43–1.11

0.1224

  Recent hospitalization

0.6951

0.55–0.87

0.0017

0.6007

0.44–0.82

0.0011

  CVD-HF

1.0782

0.92–1.26

0.3380

0.7312

0.41–1.32

0.2980

  Heart failure

2.6806

1.62–4.44

< 0.0001

5.1875

2.56–10.49

< 0.0001

  Stroke

0.6422

0.49–0.85

< 0.0001

0.9431

0.57–1.57

0.8221

  CAD

1.2914

1.09–1.53

< 0.0001

1.9390

1.10–3.40

0.0211

  PAOD

0.7000

0.40–1.22

0.2063

1.0210

0.48–2.18

0.9572

  1. Bold values denote statistical significance at the p < 0.05 level
  2. ASCVD atherosclerotic cardiovascular disease, BMI body mass index, CAD coronary artery disease, CI confidence interval, CVD-HF atherosclerotic cardiovascular disease or heart failure, DBP diastolic blood pressure, HbA1c glycosylated hemoglobin, HDL-C high-density lipoprotein cholesterol, HF heart failure, LDL-C low-density lipoprotein cholesterol, OR odds ratio, PAOD peripheral arterial occlusive disease, RAASi renin-angiotensin-aldosterone system inhibitors, SBP systolic blood pressure, SGLT2i sodium-glucose cotransporter-2 inhibitor